Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
SurModics (SRDX) Tops Q3 EPS by 10c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus
July 31, 2019 5:53 PM EDTSurModics (NASDAQ: SRDX) reported Q3 EPS of $0.15, $0.10 better than the analyst estimate of $0.05. Revenue for the quarter came in at $24.3 million versus the consensus estimate of $22.29 million.
Summary of Third Quarter and Recent Highlights
Revenue of $24.3 million, an increase of 9.5% year-over-yearGAAP EPS of $0.11, non-GAAP EPS of $0.15TRANSCEND clinical trial enrollment more than 90% completeOur third... More
